Oligonucleotide, Therapy, and Applications

Oligonucleotides (ON) constitute a new group of molecular agents, the object of significant interest due to their potential value as drugs for diagnostic and therapeutic applications. Their special interest derives from the intrinsic characteristics of ONs: a) ONs are informative agents, a property...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2022
Language:English
Physical Description:1 electronic resource (123 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545738104498
ctrlnum (CKB)5400000000045243
(oapen)https://directory.doabooks.org/handle/20.500.12854/79571
(EXLCZ)995400000000045243
collection bib_alma
record_format marc
spelling Aliño, Salvador edt
Oligonucleotide, Therapy, and Applications
Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
1 electronic resource (123 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Oligonucleotides (ON) constitute a new group of molecular agents, the object of significant interest due to their potential value as drugs for diagnostic and therapeutic applications. Their special interest derives from the intrinsic characteristics of ONs: a) ONs are informative agents, a property that derives from the order in which the nucleotides of each particular ON are arranged; b) ONs can act as ligands (ASO, TFO, aptamers, G-quadruplex, etc.) of complementary nucleic acid sequences (DNA or RNA) due to their high capacity to hybridize (by means of Watson and Crick or Hoogsteen links) with other nucleotide sequences, resulting in specific gene modulatory effects. However, nonspecific sequences may also be of interest, as is the case with repetitive nucleotide sequences (CpG) with adjuvant effects of vaccines; c) ONs can also rapidly evolve to achieve specific advantages of utility (targeting, stability, efficacy, toxicity, etc.) or high-sensitivity diagnostic technology (markers, analyzes, biosensors, FISH, microarrays, etc.), by chemical modification of nucleotides in any of their atoms. These properties show that ONs are first-order molecules due to their potential usefulness in practice.In this collection of research articles and review papers, we aim to highlight their therapeutic, but also diagnostic and technological utility as drugs.
English
Medicine bicssc
quantum dots (QDs)
DNAzyme
ROS
Amplex Red
light-induced activity
DNA methylation
histone code
microRNA
nanoparticles
noncoding RNA
pulmonary arterial hypertension
aptamer
aptasensor
influenza
SERS
virus detection
α-synuclein
antisense oligonucleotide
dopamine neurotransmission
double mutant A30P*A53T*
motor deficits
Parkinson’s disease
transgenic mouse model
G-quadruplexes
covalent dimer construct
anti-proliferative activity
primary cell culture of human glioma
antisensense oligonucleotide
Foxp3
regulatory T cells
vaccine immunogenicity
Sporothrix schenckii
Marfan syndrome
fibrillin-1
antisense oligonucleotides
exon skipping
splice-switching
3-0365-3057-6
3-0365-3056-8
Sendra, Luis edt
Aliño, Salvador oth
Sendra, Luis oth
language English
format eBook
author2 Sendra, Luis
Aliño, Salvador
Sendra, Luis
author_facet Sendra, Luis
Aliño, Salvador
Sendra, Luis
author2_variant s a sa
l s ls
author2_role HerausgeberIn
Sonstige
Sonstige
title Oligonucleotide, Therapy, and Applications
spellingShingle Oligonucleotide, Therapy, and Applications
title_full Oligonucleotide, Therapy, and Applications
title_fullStr Oligonucleotide, Therapy, and Applications
title_full_unstemmed Oligonucleotide, Therapy, and Applications
title_auth Oligonucleotide, Therapy, and Applications
title_new Oligonucleotide, Therapy, and Applications
title_sort oligonucleotide, therapy, and applications
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2022
physical 1 electronic resource (123 p.)
isbn 3-0365-3057-6
3-0365-3056-8
illustrated Not Illustrated
work_keys_str_mv AT alinosalvador oligonucleotidetherapyandapplications
AT sendraluis oligonucleotidetherapyandapplications
status_str n
ids_txt_mv (CKB)5400000000045243
(oapen)https://directory.doabooks.org/handle/20.500.12854/79571
(EXLCZ)995400000000045243
carrierType_str_mv cr
is_hierarchy_title Oligonucleotide, Therapy, and Applications
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
_version_ 1787548726668034049
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03572nam-a2200757z--4500</leader><controlfield tag="001">993545738104498</controlfield><controlfield tag="005">20231214133328.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202203s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045243</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/79571</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045243</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Aliño, Salvador</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oligonucleotide, Therapy, and Applications</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (123 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oligonucleotides (ON) constitute a new group of molecular agents, the object of significant interest due to their potential value as drugs for diagnostic and therapeutic applications. Their special interest derives from the intrinsic characteristics of ONs: a) ONs are informative agents, a property that derives from the order in which the nucleotides of each particular ON are arranged; b) ONs can act as ligands (ASO, TFO, aptamers, G-quadruplex, etc.) of complementary nucleic acid sequences (DNA or RNA) due to their high capacity to hybridize (by means of Watson and Crick or Hoogsteen links) with other nucleotide sequences, resulting in specific gene modulatory effects. However, nonspecific sequences may also be of interest, as is the case with repetitive nucleotide sequences (CpG) with adjuvant effects of vaccines; c) ONs can also rapidly evolve to achieve specific advantages of utility (targeting, stability, efficacy, toxicity, etc.) or high-sensitivity diagnostic technology (markers, analyzes, biosensors, FISH, microarrays, etc.), by chemical modification of nucleotides in any of their atoms. These properties show that ONs are first-order molecules due to their potential usefulness in practice.In this collection of research articles and review papers, we aim to highlight their therapeutic, but also diagnostic and technological utility as drugs.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">quantum dots (QDs)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNAzyme</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ROS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Amplex Red</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">light-induced activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA methylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">histone code</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microRNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanoparticles</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">noncoding RNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary arterial hypertension</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aptamer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">aptasensor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">influenza</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SERS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">virus detection</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">α-synuclein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antisense oligonucleotide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dopamine neurotransmission</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">double mutant A30P*A53T*</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">motor deficits</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Parkinson’s disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transgenic mouse model</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">G-quadruplexes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">covalent dimer construct</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-proliferative activity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">primary cell culture of human glioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antisensense oligonucleotide</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Foxp3</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">regulatory T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccine immunogenicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Sporothrix schenckii</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Marfan syndrome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fibrillin-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antisense oligonucleotides</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exon skipping</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">splice-switching</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3057-6</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3056-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sendra, Luis</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aliño, Salvador</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sendra, Luis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:50:23 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338053990004498&amp;Force_direct=true</subfield><subfield code="Z">5338053990004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338053990004498</subfield></datafield></record></collection>